Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00925782 · ClinicalTrials.gov registry record · Phase 2
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
A Phase 2 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00925782 is a Phase 2 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 24 participants.
The verdict
NCT00925782, a Phase 2 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
To assess and compare the pharmacokinetics of Melphalan HCL for Injection (Propylene Glycol-Free) versus Alkeran for Injection in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).
Interventions
- DRUG Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection
- DRUG Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00925782
The ClinicalTrials.gov registry entry for NCT00925782 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection is the first listed.
NCT00925782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00925782 about?
NCT00925782 is a clinical study titled "PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation". To assess and compare the pharmacokinetics of Melphalan HCL for Injection (Propylene Glycol-Free) versus Alkeran for Injection in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).
What is the current status of trial NCT00925782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00925782?
The interventions under investigation include: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection (DRUG), Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free) (DRUG).
Who is sponsoring clinical trial NCT00925782?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.